Drug Trial Radar · NCT06608459
PEX010-Assisted Therapy for Opioid Use Disorder (OUD): a Feasibility Study
Last checked: Nov 20, 2026Latest source record: Oct 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Dec 2024
Primary completion
Dec 2026
Study completion Jun 2027
Sponsor
- Lead sponsor
- Filament Health Corp.Industry
- Sponsor type
- Industry
- Collaborators
- University of British Columbia
- First posted
- Sep 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 25 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if it is feasible to use PEX010 for the treatment of opioid use disorder in adults. The study will also assess the safety of PEX010. The main questions it aims to answer are: Can we successfully recruit participants, provide the drug and retain participants for the duration of the study? What medical problems do participants experience when taking PEX010? Participants will: Take PEX010 twice during the study Engage in cognitive behavioural therapy Visit the clinic once or twice per week for study intervention and followup visits
Conditions
- Opioid Use Disorder
Interventions
PEX010-Assisted TherapyDrug
The investigational medicinal product PEX010 is a capsule for oral administration that contains the drug substance PYEX.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of AEs and SAEsTime frame: 8 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.